CEL-SCI Corporation Revenue and Competitors
Estimated Revenue & Valuation
- CEL-SCI Corporation's estimated annual revenue is currently $7.5M per year.
- CEL-SCI Corporation's estimated revenue per employee is $416,667
- CEL-SCI Corporation's total funding is $56.1M.
Employee Data
- CEL-SCI Corporation has 18 Employees.
- CEL-SCI Corporation grew their employee count by -10% last year.
CEL-SCI Corporation's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP Operations | Reveal Email/Phone |
2 | VP Manufacturing/Facilities/Commercial Operat | Reveal Email/Phone |
3 | Sr. VP regulatory affairs | Reveal Email/Phone |
4 | Director Manufacturing | Reveal Email/Phone |
5 | Research Associate, R&D - Vaccines Heteroconjugates | Reveal Email/Phone |
6 | Warehouse Manager | Reveal Email/Phone |
7 | Manufacturing Supervisor | Reveal Email/Phone |
8 | Director R&D and Commercial Services | Reveal Email/Phone |
9 | Associate Director Environmental Monitoring at CEL-SCI Corporation | Reveal Email/Phone |
10 | Associate Director Facilities | Reveal Email/Phone |
CEL-SCI Corporation Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.4M | 9 | -10% | N/A | N/A |
#2 | $4.3M | 28 | 4% | N/A | N/A |
#3 | $1.1M | 7 | 0% | N/A | N/A |
#4 | $3.5M | 45 | -52% | $56.5M | N/A |
#5 | $0.3M | 2 | 0% | N/A | N/A |
#6 | $4.5M | 29 | 21% | N/A | N/A |
#7 | $1.9M | 12 | 9% | N/A | N/A |
#8 | $7M | 45 | 5% | N/A | N/A |
#9 | $6.7M | 43 | 5% | N/A | N/A |
#10 | $2M | 13 | -13% | N/A | N/A |
What Is CEL-SCI Corporation?
CEL-SCI\'s story is one of vision, persistence, and survival in the face of overwhelming odds. Despite downturns in the biotech sector, lack of funding, and a lengthy clinical trial process associated with the development of its investigational therapy for advanced primary head and neck cancer, CEL-SCI is finally approaching the end game! Our lead investigational immunotherapy, Multikine® (Leukocyte Interleukin, Injection), has been tested in Phase I and II clinical trials, and is now enrolling patients for a global Phase III trial. Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.
keywords:Biotechnology
$56.1M
Total Funding
18
Number of Employees
$7.5M
Revenue (est)
-10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
CEL-SCI Corporation News
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that two abstracts related to CEL-SCI's pivotal Phase...
CEL-SCI Corporation (CVM) stock is lower by -82.47% over the last 12 months, and the average rating from Wall Street analysts is a Strong...
CEL-SCI Corporation (CVM) is down Tuesday morning, with the stock declining -6.81% in pre-market trading to 3.42. CVM's short-term technical...
Other Companies in Wolf Trap
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.7M | 19 | -14% | N/A |
#2 | $2.6M | 26 | N/A | N/A |
#3 | $4.2M | 27 | 29% | N/A |
#4 | $2M | 28 | 4% | $13.6M |
#5 | $2.1M | 29 | 7% | $53M |